Abstract: The invention relates to a method for a more appropriate thromboembolic event risk assessment based on the presence of different genetic variant. The invention also relates to a method for determining the risk of suffering a thromboembolism disease by combining the absence or presence of one or more polymorphic markers in a sample from the subject with conventional risk factors for thromboembolism as well as computer-implemented means for carrying out said method.
Type:
Grant
Filed:
October 19, 2015
Date of Patent:
July 17, 2018
Assignee:
Gendiag.exe, S.L.
Inventors:
Eduardo Salas, José Manuel Soria, Miroslava Ogorelkova, Roberto Elosua, Joan S. Vila, Sergio Castillo
Abstract: Provided herein is technology relating to performing methylation assays. In particular, the technology relates to internal controls for methylation assays.
Type:
Grant
Filed:
December 11, 2015
Date of Patent:
July 3, 2018
Assignee:
Exact Sciences Development Company
Inventors:
David Alan Ahlquist, William Russell Taylor, Douglas W. Mahoney, Graham P. Lidgard, Hatim T. Allawi, Abram Michael Vaccaro
Abstract: A method of determining the risk of cognitive decline in an aging subject is provided. The method includes analyzing an MRNA transcript including a GRIN2B nucleic acid sequence for the presence of the A allele in a biological sample obtained from the subject. The method also includes identifying the subject as having a decreased risk of cognitive decline when the A allele is present.
Type:
Grant
Filed:
May 8, 2017
Date of Patent:
July 3, 2018
Assignee:
INOVA HEALTH SYSTEM
Inventors:
Robert H. Lipsky, Mingkuan Lin, Yang Jiang
Abstract: [PROBLEM TO BE SOLVED] An object of the present invention is to provide a novel tumor marker and use thereof. In more detail, the present invention provides a novel tumor marker, a method for measuring said tumor marker and a measurement kit, a method for detecting cancer using the same, a kit for detecting cancer, a method for screening a preventive and/or therapeutic agent for cancer, as well as a medicament such as cancer vaccine. [SOLUTION] According to the present invention, a method for measuring an alternative splicing variant of OATP1B3 mRNA in a sample to be examined is provided. Said measurement method comprises measuring mRNA comprising a nucleotide sequence represented by SEQ ID NO: 1 in the sequence listing table in a sample to be examined isolated from living organism with differentiation from a mRNA comprising a nucleotide sequence represented by SEQ ID NO: 2. Said measurement method is useful for detecting cancer or screening a preventive and/or therapeutic agent.
Type:
Grant
Filed:
August 2, 2016
Date of Patent:
July 3, 2018
Assignee:
National University Corporation China University
Inventors:
Tomomi Furihata, Sayaka Matsumoto, Miki Nagai, Kan Chiba
Abstract: Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting premalignant and malignant neoplasms such as gastric cancer.
Type:
Grant
Filed:
August 31, 2016
Date of Patent:
June 26, 2018
Assignees:
Mayo Foundation for Medical Education and Research, EXACT SCIENCES DEVELOPMENT COMPANY, LLC
Inventors:
David A. Ahlquist, William R. Taylor, John B. Kisiel, Tracy C. Yab, Douglas W. Mahoney, Hatim T. Allawi
Abstract: Methods and kits are provided for diagnosing, monitoring, or predicting preeclaimpsia in a pregnant woman, trisomy 18 and trisomy 21 in a fetus, as well as for detecting pregnancy in a woman, by quantitatively measuring in the maternal blood the amount of one or more RNA species derived from a set of genetic loci and comparing the amount of the RNA species with a standard control.
Type:
Grant
Filed:
April 13, 2015
Date of Patent:
June 26, 2018
Assignee:
The Chinese University of Hong Kong
Inventors:
Yuk-Ming Dennis Lo, Rossa Wai Kwun Chiu, Stephen Siu Chung Chim, Nancy Bo Yin Tsui
Abstract: Disclosed are nucleic acid molecules from the genome of Dirofilaria spp. nematodes that contain single nucleotide polymorphisms related to reduced responsiveness of the nematodes to macrocyclic lactones. In one example, the species of Dirofilaria is Dirofilaria immitis (the agent of heartworm in animals). Also disclosed are methods for determining the responsiveness of Dirofilaria spp. nematodes to macrocyclic lactones, methods for selecting a treatment to treat an animal infected with a Dirofilaria spp. nematode, and kits for determining the responsiveness of Dirofilaria spp. nematodes to macrocyclic lactones.
Type:
Grant
Filed:
June 25, 2014
Date of Patent:
June 19, 2018
Assignee:
Elanco US Inc. and McGill University
Inventors:
Roger K. Prichard, Catherine Bourguinat, Timothy G. Geary
Abstract: Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting premalignant and malignant neoplasms such as pancreatic and colorectal cancer. Accordingly, provided herein is technology for pancreatic cancer screening markers and other gastrointestinal cancer screening markers that provide a high signal to-noise ratio and a low background level when detected from samples taken from a subject (e.g., stool sample). As described herein, the technology provides a number of methylated DNA markers and subsets thereof (e.g., sets of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more markers) with high discrimination for G1 neoplasms overall and/or at individual tumor sites.
Type:
Grant
Filed:
March 12, 2014
Date of Patent:
June 12, 2018
Assignees:
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH, EXACT SCIENCES DEVELOPMENT COMPANY, LLC
Inventors:
David A. Ahlquist, John B. Kisiel, William R. Taylor, Tracy C. Yab, Douglas W. Mahoney, Graham P. Lidgard, Hatim T. Allawi
Abstract: Methods and kits for diagnosing, prognosticating risk of, and selecting and/or administering a therapy for breast cancer based upon detection of methylated glucocorticoid receptor gene or measurement of glucocorticoid receptor and BRCA1 gene expression levels are provided.
Type:
Grant
Filed:
March 11, 2014
Date of Patent:
June 5, 2018
Assignee:
QUEEN'S UNIVERSITY AT KINGSTON
Inventors:
Christopher Robert Mueller, Kirsten A. Nesset
Abstract: Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting premalignant and malignant neoplasms such as pancreatic and colorectal cancer.
Type:
Grant
Filed:
August 22, 2016
Date of Patent:
May 29, 2018
Assignee:
Mayo Foundation for Medical Education and Research
Inventors:
David A. Ahlquist, John B. Kisiel, William R. Taylor, Tracy C. Yab, Douglas W. Mahoney
Abstract: Different combinations of methylation status based biomarkers can be used to test for prostate cancer with high sensitivity and high specificity.
Type:
Grant
Filed:
June 11, 2013
Date of Patent:
May 22, 2018
Assignee:
KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY
Inventors:
Vladimir Bajic, Hicham Mansour, Roberto Incitti
Abstract: The present invention compositions, methods and systems to identify, detect, and/or quantify bacterial DNA in the presence of contaminating non-bacterial DNA. In particular, the present invention provides oligonucleotides configured to detect a relatively small amount of bacterial DNA in the presence of an overwhelmingly large amount of contaminating human DNA.
Type:
Grant
Filed:
December 27, 2012
Date of Patent:
May 15, 2018
Assignee:
IBIS BIOSCIENCES, INC.
Inventors:
David J. Ecker, Steven A. Hofstadler, Rangarajan Sampath, Lawrence B. Blyn, Thomas A. Hall, Mark W. Eshoo
Abstract: Methods and compositions disclosed herein generally relate to methods of improving clinical and economic outcomes to address adverse effects related to anesthesia, analgesics, opioids, and inadequate pain relief. Embodiments of the invention relate to the association between genes, specific polymorphisms of genes, and non-genetic factors with inadequate pain relief and anesthesia-, analgesic, and/or opioid-related adverse effects. Embodiments of the invention can be used to determine and manage patient risk factors for development of adverse perioperative effects and can allow for personalized anesthesia and pain management for improvement of pain control and reduction of anesthesia-, analgesic-, and opioid-related adverse outcomes. These methods and compositions apply to non-surgical pain management with opioids.
Type:
Grant
Filed:
November 29, 2012
Date of Patent:
April 17, 2018
Assignee:
Children's Hospital Medical Center
Inventors:
Senthilkumar Sadhasivam, Vidya Chidambaran, John McAuliffe, Kejian Zhang, Jarolsaw Meller, Cynthia A. Prows, Tsuyoshi Fukuda
Abstract: The present invention relates to a method, in particular an in vitro method, for identifying CD3CD4 positive T lymphocytes of a mammal, wherein the method comprises analyzing the bisulfite convertibility of at least one CpG position in the CD3+CD4+ T helper cell specific non-methylated bisulfite convertible region according to SEQ ID No. 1, wherein a bisulfite convertibility of at least one CpG position to at least 90%, preferably to at least 91% and more preferably to at least 92% and most preferred to at least 95% in the sample is indicative for a CD4+ T-lymphocyte cell, in particular a CD3+CD4+ T-lymphocyte cell. The present invention further relates to analyzing the bisulfite convertibility of at least one CpG position in the genes FLJ00060, FLJ38379, PPP6C, CD226, ZBTB7B and TNFAIP8 that are capable of positively identifying CD4 expressing cells in whole blood and segregate between CD4 and CD8 positive CD3 positive cells.
Abstract: Disclosed are methods, compositions, and diagnostic kits for the rapid detection of certain types of ?-thalassemia and ?-thalassemia. In some embodiments, a diagnostic kit, reagents, and methods are disclosed for the rapid detection of various ?-thalassemia and ?-thalassemia genotypes in multiple patient samples using real-time PCR. More specifically, in certain embodiments, diagnostic kits, reagents, and methods are disclosed for the rapid detection of up to seven different ?-thalassemia genotypes and twenty different ?-thalassemia genotypes in one single multiplex real-time PCR reaction.
Type:
Grant
Filed:
August 23, 2017
Date of Patent:
March 6, 2018
Assignee:
URIT Medical Electronic Co., Ltd.
Inventors:
Tom Cheng Xu, Jun Liu, Chengfeng Jiang, Jinlan Xu, Lili Sun
Abstract: Described herein is a set of oligonucleotide probes. Also included are methods of using the oligonucleotide probes in profiling the microbiota of the GI tract of a subject and methods of diagnosing or monitoring a disease or condition in a subject or predicting or assessing the risk of a subject developing a disease or condition. Kits comprising the oligonucleotide probe set described herein are also provided.
Abstract: The invention relates to methods of depleting RNA from a nucleic acid sample. The RNA may be any RNA, including, but not limited to, rRNA, tRNA, and mRNA. The method is useful for depleting RNA from a nucleic acid sample obtained from a fixed paraffin-embedded tissue (FPET) sample. The method may also be used to prepare cDNA, in particular, a cDNA library for further analysis or manipulation.
Abstract: The present invention relates to methods of assessing whether a subject has or is likely to develop a neurodegenerative disease comprising determining whether the subject has a mutation in the C9orf72 gene wherein said mutation prevents or disrupts C9orf72 expression relative to expression in a reference from subjects without the mutation.
Type:
Grant
Filed:
August 31, 2012
Date of Patent:
February 20, 2018
Assignees:
The University of Manchester, National Institute of Aging, Hospital District of Helsinki and UUSIMAA, VU University Medical Centre Armsterdam, UCL Business PLC, University College Cardiff Consultants Limited
Inventors:
Stuart Pickering-Brown, Bryan Traynor, Andrew B. Singleton, Huw Morris, Peter Heutink, John Hardy, Pentti Tienari
Abstract: The invention relates to method for detecting HPV-induced high-grade precancerous lesions and HPV-induced invasive cancers, said method comprising detection of hypermethylation in the PRDM14 and/or FAM19A4 gene in a cell whereby such hypermethylation indicates the presence of HPV-induced precursor lesions with invasive potential and HPV-induced invasive cancers. The invention further comprises the use of the PRDM14 and/or FAM19A4 gene in such a method and a testkit for the detection of PRDM14 and/or FAM19A4 methylation.
Type:
Grant
Filed:
October 14, 2013
Date of Patent:
February 13, 2018
Assignee:
SELF-SCREEN B.V.
Inventors:
Christophorus Joannes Lambertus Maria Meijer, Petrus Josephus Ferdinandus Snijders, Renske Daniëla Maria Steenbergen